Milestone Pharmaceuticals (MIST) Set to Post Quarterly Earnings on Wednesday

Milestone Pharmaceuticals (NASDAQ:MIST) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Milestone Pharmaceuticals to announce earnings of ($0.20) per share and revenue of $1.00 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The business had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $0.82 million. On average, analysts expect Milestone Pharmaceuticals to post ($0.84) EPS for the current fiscal year and ($0.78) EPS for the next fiscal year.

Milestone Pharmaceuticals Stock Performance

Shares of MIST traded down $0.01 during mid-day trading on Wednesday, hitting $0.75. 155,541 shares of the company’s stock were exchanged, compared to its average volume of 1,720,448. The company has a quick ratio of 7.92, a current ratio of 8.13 and a debt-to-equity ratio of 3.25. Milestone Pharmaceuticals has a 52 week low of $0.63 and a 52 week high of $3.06. The stock’s 50-day simple moving average is $0.88 and its 200-day simple moving average is $1.36. The firm has a market cap of $93.87 million, a price-to-earnings ratio of -1.10 and a beta of 1.07.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald began coverage on Milestone Pharmaceuticals in a research report on Thursday, August 20th. They set an “overweight” rating and a $3.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Milestone Pharmaceuticals in a report on Thursday, September 3rd. Zacks Research raised Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Milestone Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $6.40.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s research is centered on treatments designed to provide rapid, patient-administered relief for episodic cardiovascular disorders.

Milestone’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. The therapy has been developed primarily for the treatment of paroxysmal supraventricular tachycardia, or PSVT, a condition characterized by episodes of abnormally rapid heart rate.